News & Updates

A small but promising study showed that acalabrutinib, an oral BTK* inhibitor approved for B-cell malignancies**, may reduce or even prevent clinical reactivity to peanuts in peanut-allergic adults.

Data from a French study presented at CROI 2023 support the use of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/FTC/TAF) in the management of paediatric patients with HIV.

Treatment with rifaximin appears to produce significant reductions in multiple, concurrent symptoms of irritable bowel syndrome (IBS) with diarrhoea, according to a study that uses a novel tri-symptom endpoint.

The use of bempedoic acid significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with high cholesterol who are intolerant to statins in the phase III CLEAR* Outcomes trial presented at ACC.23/WCC.

In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).